×
About 5,770 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  2,783 results

Age and remission induction therapy for acute myeloid leukemia: An analysis of data fro...
https://doi.org/10.1371/journal.pone.0251011
PloS One; Yoo KH, Kim HJ et. al.

May 7th, 2021 - The clinical characteristics and therapeutic strategy in acute myeloid leukemia (AML) are influenced by patients' age. We evaluated the impact of age on remission induction therapy for AML. We retrospectively analyzed 3,011 adult AML patients iden...

Successful treatment of acute promyelocytic leukemia in a patient with prosthetic heart...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094532
Journal of Medical Case Reports; Haghighat S, Rezvani A et. al.

May 4th, 2021 - Although life-threatening hemorrhage is a usual manifestation of acute promyelocytic leukemia (APL), thrombotic events seem to be more common in APL compared to other subtypes of acute leukemia. The treatment and prophylaxis of thrombosis are cont...

Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Pop...
https://doi.org/10.1016/j.clml.2021.03.010
Clinical Lymphoma, Myeloma & Leukemia; Wang CY, Huang HH et. al.

May 1st, 2021 - Acute myeloid leukemia (AML) is a hematological malignancy originating from myeloid precursor cells, with different cytogenetic abnormalities, genetic mutations and diverse clinical prognoses. We investigated the clinical characteristics, treatmen...

Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in P...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071704
Drug Design, Development and Therapy; Zhang L, Yang XM et. al.

Apr 29th, 2021 - An oral tetra-arsenic tetra-sulfide (AS4S4) formula has been recommended as an outpatient post-remission treatment for Chinese adults with acute promyelocytic leukemia (APL) but limited data are available for children. In this exploratory study, w...

see more →

Guidelines  2 results

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement o...
http://ascopubs.org/doi/10.1200/JCO.18.01468
de Haas, V.

Dec 2nd, 2018 - The College of American Pathologists (CAP) and the American Society of Hematology (ASH) developed an evidence-based guideline on the initial diagnostic work-up of acute leukemia (AL). Because of the relevance of this topic to the ASCO membership,.

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 13th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  23 results see all →

Clinicaltrials.gov  2,885 results

Age and remission induction therapy for acute myeloid leukemia: An analysis of data fro...
https://doi.org/10.1371/journal.pone.0251011
PloS One; Yoo KH, Kim HJ et. al.

May 7th, 2021 - The clinical characteristics and therapeutic strategy in acute myeloid leukemia (AML) are influenced by patients' age. We evaluated the impact of age on remission induction therapy for AML. We retrospectively analyzed 3,011 adult AML patients iden...

Successful treatment of acute promyelocytic leukemia in a patient with prosthetic heart...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094532
Journal of Medical Case Reports; Haghighat S, Rezvani A et. al.

May 4th, 2021 - Although life-threatening hemorrhage is a usual manifestation of acute promyelocytic leukemia (APL), thrombotic events seem to be more common in APL compared to other subtypes of acute leukemia. The treatment and prophylaxis of thrombosis are cont...

Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Pop...
https://doi.org/10.1016/j.clml.2021.03.010
Clinical Lymphoma, Myeloma & Leukemia; Wang CY, Huang HH et. al.

May 1st, 2021 - Acute myeloid leukemia (AML) is a hematological malignancy originating from myeloid precursor cells, with different cytogenetic abnormalities, genetic mutations and diverse clinical prognoses. We investigated the clinical characteristics, treatmen...

Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in P...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071704
Drug Design, Development and Therapy; Zhang L, Yang XM et. al.

Apr 29th, 2021 - An oral tetra-arsenic tetra-sulfide (AS4S4) formula has been recommended as an outpatient post-remission treatment for Chinese adults with acute promyelocytic leukemia (APL) but limited data are available for children. In this exploratory study, w...

see more →

News  77 results

How to Treat Differentiation Syndrome in APL and AML
https://decisionpoint.medscape.com/oncology/viewarticle/936167

Sep 17th, 2020 - This transcript has been edited for clarity. Differentiation syndrome is a frequent complication while patients have active acute promyelocytic leukemia (APL). First of all, we need to mention that the diagnosis of differentiation syndrome is base...

Don't Overlook Treating Older Patients With Acute Promyelocytic Leukemia, Expert Says
https://www.medscape.com/viewarticle/934124

Jul 16th, 2020 - The estimated one third of patients with acute promyelocytic leukemia (APL) who are older than 60 years of age now enjoy a notably better prognosis than in years past, thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxi...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.staging.medscape.com/viewarticle/917519

Aug 29th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.medscape.com/viewarticle/917519

Aug 29th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

see more →